Tolremo
TOLREMO therapeutics develops small molecule inhibitors designed to prevent non-genetic drug resistance in cancer by blocking transcriptional escape pathways. The company's lead clinical compound, TT125-802, targets the CBP/p300 epigenetic regulator to treat solid tumors and hematological malignancies. Their approach focuses on using these inhibitors both as monotherapies and in combination with existing targeted therapies to provide more durable patient benefits.
Biotechnology
Oncology
Pharmaceuticals
Funding summary
- Total raised
- €8.0M
- Funding rounds
- 1
Investors in Tolremo
Investors on record for Tolremo. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Tolremo?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors